Roche became the latest company to join Ending Workplace TB (EWTB) at a special event hosted by Johnson & Johnson and the Global Fund to Fight HIV/AIDS, TB and Malaria on the fringes of the World Economic Forum's Annual Meeting at Davos-Klosters.
The event brought together senior executives from leading companies to consider the role that the private sector could play in supporting global health, and particularly in efforts to get the fight against infectious diseases back on track.
Shyam Bishen, Head of Health and Healthcare at the World Economic Forum opened the meeting, before Peter Sands, Executive Director of the Global Fund, gave his perspectives on the role of the private sector. Senior executives, including Christoph Franz, Chairman of Roche, Alexandra von Plato, CEO of PublicisHealth, and Stuart Chambers, Chairman of Anglo-American, outlined their visions for the role that companies could play.
Roche become the 28th company to join the Ending Workplace TB initiative as part of its broad commitments to
global health, and particularly TB. Founded in 1896 in Basel, Switzerland, Roche is the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world and is increasingly focused on health insights. It has over 100,000 employees in 150 countries as is one of the biggest in the EWTB network.
We're delighted to welcome them on board and look forward to working with Roche to tackle TB in the workplace and wherever it is found.
